Hoe verhoudt 950's PE Ratio zich tot zijn concurrenten?

950 is duur op basis van de Price-To-Earnings -ratio ( 11.4 x) vergeleken met het gemiddelde van de peer ( 8 x).

Hoe verhoudt 950's PE Ratio zich tot andere bedrijven in de HK Pharmaceuticals industrie?

950 is duur op basis van de Price-To-Earnings -ratio ( 11.4 x) vergeleken met het Hong Kong Pharmaceuticals -industriegemiddelde ( 8 x).

Wat is 950's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Earnings Fair Ratio van { 950 te berekenen voor waarderinganalyse.

Wat is de reële prijs van 950 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

950 ( HK$1.22 ) handelt boven onze schatting van [[eerlijke waarde]] ( HK$0.66 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Lee's Pharmaceutical Holdings (SEHK:950) - Aandelenkoers, Nieuws & Analyse

950 Overzicht aandelen

Lee's Pharmaceutical Holdings Limited, een investeringsholding, ontwikkelt, produceert, verkoopt en verhandelt farmaceutische producten voornamelijk in de Volksrepubliek China. Meer informatie

950 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	4/6
Financiële gezondheid	5/6
Dividenden	1/6

Beloningen

De winst groeide het afgelopen jaar met 61.9%

Risicoanalyse

De winst is de afgelopen 5 jaar met 14.9% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( HK$718M )

Lee's Pharmaceutical Holdings Limited Concurrenten

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$767.5m

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$820.4m

Pak Fah Yeow International

SEHK:239

HK$766.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Lee's Pharmaceutical Holdings
Historische aandelenkoersen
Huidige aandelenkoers	HK$1.22
52 Week Hoogtepunt	HK$1.75
52 Week Laag	HK$1.00
Bèta	0.87
11 maand verandering	-2.40%
3 maanden verandering	-0.81%
1 Jaar Verandering	-2.40%
33 jaar verandering	-64.64%
5 jaar verandering	-68.96%
Verandering sinds IPO	134.62%

Recent nieuws en updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Rendement voor aandeelhouders

	950	HK Pharmaceuticals	HK Markt
7D	-4.7%	0.07%	-0.6%
1Y	-2.4%	-10.2%	9.6%

Rendement versus industrie: 950 overtrof de Hong Kong Pharmaceuticals industrie, die het afgelopen jaar een rendement -10.2 % opleverde.

Rendement versus markt: 950 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 9.6 % opleverde.

Prijsvolatiliteit

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement	6.9%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.2%
10% least volatile stocks in HK Market	4.3%

Stabiele aandelenkoers: 950 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 950 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1994	993	n/a	www.leespharm.com

Lee's Pharmaceutical Holdings Limited, een investeringsholding, ontwikkelt, produceert, verkoopt en verhandelt farmaceutische producten voornamelijk in de Volksrepubliek China. Het bedrijf richt zich op verschillende ziektegebieden, waaronder hart- en vaatziekten, vrouwengeneeskunde, kindergeneeskunde, zeldzame ziekten, oncologie, dermatologie en verloskunde. Het bedrijf is actief in de segmenten Eigen en Generieke Producten en Licentieproducten.

Lee's Pharmaceutical Holdings Limited Samenvatting

Hoe verhouden de winst en inkomsten van Lee's Pharmaceutical Holdings zich tot de beurswaarde?
950 fundamentele statistieken
Marktkapitalisatie	HK$718.38m
Inkomsten(TTM)	HK$63.06m
Inkomsten(TTM)	HK$1.20b

11.4x

Koers/Winstverhouding

0.6x

P/S-verhouding

Is 950 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
950 resultatenrekening (TTM)
Inkomsten	HK$1.20b
Kosten van inkomsten	HK$581.63m
Brutowinst	HK$617.44m
Overige uitgaven	HK$554.38m
Inkomsten	HK$63.06m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.11
Brutomarge	51.49%
Nettowinstmarge	5.26%
Schuld/Eigen Vermogen Verhouding	14.2%

Hoe presteerde 950 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.5%

Huidig dividendrendement

28%

Uitbetalingsratio

950 Overzicht aandelen

Beloningen

Risicoanalyse

Lee's Pharmaceutical Holdings Limited Concurrenten

SEHK:503

HK$750.6m

SEHK:8049

HK$767.5m

SEHK:3737

HK$820.4m

SEHK:239

HK$766.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022